MBDB

PharmAla Biotech Signs Sale Agreement with Numinus

Retrieved on: 
Tuesday, March 26, 2024
MDXX, MBDB, GMP, TSX, OTCQX, Clinical trial, OTC, MDMA, ABA, Biology, Poster, Pharmaceutical industry

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA, OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it had entered into a binding sales agreement with Numinus Wellness Inc. (“Numinus”) (TSX: NUMI, OTCQX: NUMIF) to provide its GMP LaNeo™ MDMA for a prospective clinical trial.

Key Points: 
  • TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA, OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it had entered into a binding sales agreement with Numinus Wellness Inc. (“Numinus”) (TSX: NUMI, OTCQX: NUMIF) to provide its GMP LaNeo™ MDMA for a prospective clinical trial.
  • “PharmAla wishes Numinus success in their clinical trial application, and looks forward to supporting them in their efforts,” said Nick Kadysh, Founding CEO, PharmAla Biotech.
  • The poster, entitled In Vivo Characterization of MBDB and its Enantiomers in C57 and Autism-like BTBR Mice, presents key findings from the development of PharmAla’s proof-of-concept rodent data for its ABA molecule family.
  • “We thank Dr. Fantegrossi for his exceptional and diligent work, and look forward to receiving academic community feedback on our findings thus far,” said Dr. Harpreet Kaur, Vice President of Research, PharmAla Biotech.

Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application.

Retrieved on: 
Friday, May 26, 2023
MDAI, Therapy, MEAI, PTSD, PCT, MDE, Literature, Patent, Post-traumatic stress disorder, Patient, USE, MBDB, Empathy, Terran, SALTS, MDMA, MDEA, Pharmaceutical industry

MDMA is the most studied empathogen to date and has been shown to be an effective treatment for post-traumatic stress disorder (PTSD) in multiple phase 3 trials.

Key Points: 
  • MDMA is the most studied empathogen to date and has been shown to be an effective treatment for post-traumatic stress disorder (PTSD) in multiple phase 3 trials.
  • Historically, MDMA has only been developed as a single salt and the crystal structures of its enantiomers had not been characterized.
  • As previously reported, Terran found that the S enantiomer of MDEA had significant advantages over the (R)-MDEA in preclinical models.
  • Terran is also developing the S enantiomer of MBDB which was shown to have significant advantages over (R)-MBDB in preclinical models.

Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB

Retrieved on: 
Thursday, May 11, 2023
MDMC, REMS, MDAI, Depression, Therapy, MDEA, Mitigation, Methylone, Anxiety, Therapeutic index, Pathology, Pharmacokinetics, PCT, MDE, DSM-IV codes, Literature, OF, Patent, Patient, Post-traumatic stress disorder, USE, MBDB, Empathy, Salt, SALTS, MDMA, Safety, Pharmaceutical industry, Vaccine, Terran, PTSD

The discoveries include novel deuterated forms, enantiomerically pure forms, as well as novel salts, polymorphs, and co-crystals of racemic methylone, R-methylone and S-methylone.

Key Points: 
  • The discoveries include novel deuterated forms, enantiomerically pure forms, as well as novel salts, polymorphs, and co-crystals of racemic methylone, R-methylone and S-methylone.
  • Terran believes that therapeutic options for patients should be equally diverse, with unique psychedelics and empathogens tailored to specific patient needs.
  • Terran completed what is believed to be the first comprehensive salt and polymorph screen performed to date on this compound.
  • Terran completed additional improvements including the synthesis of deuterated forms of racemic methylone, R-methylone, and S-methylone with improved pharmacokinetics.

Patent Application Published for PharmAla Biotech’s MDMA Analogs

Retrieved on: 
Thursday, February 23, 2023
Clinical trial, UAMS, Safety, Pharmacology, University, Toxicology, Research, CSE, ABA, University of Arkansas School of Law, GMP, NCE, Hyperthermia, MDMA, Cardiotoxicity, PCT, Medicine, ALA, Patent Cooperation Treaty, MBDB, Pharmaceutical industry, Dietary supplement

VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) is pleased to announce the publication of a key Patent Cooperation Treaty (PCT) application containing 6 Novel Chemical Entities (NCEs).

Key Points: 
  • VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) is pleased to announce the publication of a key Patent Cooperation Treaty (PCT) application containing 6 Novel Chemical Entities (NCEs).
  • The application claims priority to and benefit of a United States provisional patent application filed on August 20, 2021.
  • This PCT application disclosed novel compositions of MDMA and analogs thereof, which may be used to alleviate the known side effects of MDMA while retaining its efficacy.
  • The PharmAla Patent Application also countenances the composition of 3 novel compositions of 1,3-benzodioxolyl-N-methylbutanamine (MBDB), a lesser-known analog of MDMA, which also presents an improved toxicology profile based on animal models; PharmAla refers to these compositions as the ABA series.